These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 10579076)
1. Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen? Chang SS; Bander NH; Heston WD Curr Opin Urol; 1999 Sep; 9(5):391-5. PubMed ID: 10579076 [TBL] [Abstract][Full Text] [Related]
2. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791 [TBL] [Abstract][Full Text] [Related]
4. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Liu H; Moy P; Kim S; Xia Y; Rajasekaran A; Navarro V; Knudsen B; Bander NH Cancer Res; 1997 Sep; 57(17):3629-34. PubMed ID: 9288760 [TBL] [Abstract][Full Text] [Related]
6. The clinical role of prostate-specific membrane antigen (PSMA). Chang SS; Heston WD Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535 [TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653 [TBL] [Abstract][Full Text] [Related]
9. Target antigens for prostate cancer immunotherapy. Saffran DC; Reiter RE; Jakobovits A; Witte ON Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787 [TBL] [Abstract][Full Text] [Related]
10. Antibody therapeutics for treating prostate cancer: where are we now and what comes next? Vlachostergios PJ; Galletti G; Palmer J; Lam L; Karir BS; Tagawa ST Expert Opin Biol Ther; 2017 Feb; 17(2):135-149. PubMed ID: 27817214 [TBL] [Abstract][Full Text] [Related]
12. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563 [TBL] [Abstract][Full Text] [Related]
13. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847 [TBL] [Abstract][Full Text] [Related]
14. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975 [TBL] [Abstract][Full Text] [Related]
15. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Elsässer-Beile U; Bühler P; Wolf P Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907 [TBL] [Abstract][Full Text] [Related]
17. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129 [TBL] [Abstract][Full Text] [Related]
18. Expression of the prostate-specific membrane antigen. Israeli RS; Powell CT; Corr JG; Fair WR; Heston WD Cancer Res; 1994 Apr; 54(7):1807-11. PubMed ID: 7511053 [TBL] [Abstract][Full Text] [Related]
19. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Liu H; Rajasekaran AK; Moy P; Xia Y; Kim S; Navarro V; Rahmati R; Bander NH Cancer Res; 1998 Sep; 58(18):4055-60. PubMed ID: 9751609 [TBL] [Abstract][Full Text] [Related]
20. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Chang SS; Reuter VE; Heston WD; Gaudin PB Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]